FDA approves Foamix company Amzeeq for treatment of inflammatory lesions in acne patients

recently, Foamix Pharmaceuticals(http:// announcedthat the U.SFDA(http://approved the company's Amzeeq (minocycline, formerly known as FMX101) for the treatment of inflammatory lesions (adults and pediatric patients over 9 years of age) who are non-hospitalized to severe acne patientsAmzeeq is a 4% concentration of minocyclic foam therapy, the first FDA-approved topical minocyclin therapyAmzeeq is a 4% minocyclic exofoam developed by FoamixMinocycline is a broad-spectrum antibiotic that has significant efficacy in the treatment of severe acne in the treatmentFor a long time, however, there was only an oral dosage form, and for some patients, the systemic side effects of minocycline prevented them from using this effective treatmentUsing the company's unique Molecular Stabilizing Technology, MST platform, Foamix has developed a foam-based dosage that allows patients to use it once a day to deliver minocycline to the skin effectivelyThis approval was supported by the results of three Phase 3 clinicaltrials(http://, comprising a total of 2,418 patients over the age of 9In these trials, Amzeeq significantly reduced the number of inflammatory lesions in patients compared to the vector control groupalso using the researchers' overall assessment (IGA) score, Amzeeq also significantly improved the IGA score to 0 or 1 (meaning that skin symptoms were completely cleared or nearly completely cleared), or igA increased by at least 2 points over the baseline